Daniel Carvalho de Menezes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Carvalho de Menezes has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Juarez Antônio Simões Quaresma
Department of Pathology, Paulista School of Medicine, Federal University of São Paulo, São Paulo 04023-062, SP, Brazil
6 shared publications - Luiz Fábio Magno Falcão
Universidade do Estado do Pará, Brazil
6 shared publications - Igor Costa de Lima
Center for Biological Health Sciences, State University of Pará, Belém 66087670, Brazil
3 shared publications - Patrícia Danielle Lima de Lima
Universidade do Estado do Pará
3 shared publications - Pedro Fernando da Costa Vasconcelos
Centre for Biological and Health Sciences, University of Pará State, Belém 66087-662, PA, Brazil
3 shared publications - Pedro Fernando da Costa Vasconcelos
Center for Biological Health Sciences, State University of Pará (UEPA), Belém 66087-670, Brazil
3 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (8) , 1013
Persistent Redox Imbalance in Post-COVID-19 Syndrome: Lipid Peroxidation, Antioxidant Enzyme Depletion, and Reduced Nitric Oxide Availability in an Amazonian Population
Post-COVID-19 syndrome (PCS) can persist even after mild acute illness, and oxidative stress has been proposed as a central mechanism for this persistence, although it remains poorly studied in the Amazon. This study characterized redox imbalance in patients with PCS through a combined analysis of lipid peroxidation, antioxidant defenses, and nitric oxide bioavailability. In a cross-sectional observational design, 85 patients with PCS and 53 healthy controls were evaluated, with determination of TBARS, total antioxidant capacity (ABTS), erythrocyte SOD, CAT, and GPx activity, plasma nitric oxide levels, and subgroup analysis according to disease duration (≤6, 6–12, and >12 months). Patients with PCS showed significantly higher TBARS concentrations and lower nitric oxide, ABTS, SOD, CAT, and GPx levels than controls, with predominantly large effect sizes. Lipid peroxidation correlated positively with HDL-c levels, and none of the markers differed significantly among the symptom duration subgroups. The findings indicate that PCS is associated with a persistent redox imbalance, marked by continuous lipid oxidative damage and sustained depletion of enzymatic and non-enzymatic antioxidant defenses, with a vascular component suggested by reduced nitric oxide levels, regardless of the time elapsed since symptom onset.
- 14 August 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (8) , 1013
Open AccessPersistent Redox Imbalance in Post-COVID-19 Syndrome: Lipid Peroxidation, Antioxidant Enzyme Depletion, and Reduced Nitric Oxide Availability in an Amazonian Population
Post-COVID-19 syndrome (PCS) can persist even after mild acute illness, and oxidative stress has been proposed as a central mechanism for this persistence, although it remains poorly studied in the Amazon. This study characterized redox imbalance in patients with PCS through a combined analysis of lipid peroxidation, antioxidant defenses, and nitric oxide bioavailability. In a cross-sectional observational design, 85 patients with PCS and 53 healthy controls were evaluated, with determination of TBARS, total antioxidant capacity (ABTS), erythrocyte SOD, CAT, and GPx activity, plasma nitric oxide levels, and subgroup analysis according to disease duration (≤6, 6–12, and >12 months). Patients with PCS showed significantly higher TBARS concentrations and lower nitric oxide, ABTS, SOD, CAT, and GPx levels than controls, with predominantly large effect sizes. Lipid peroxidation correlated positively with HDL-c levels, and none of the markers differed significantly among the symptom duration subgroups. The findings indicate that PCS is associated with a persistent redox imbalance, marked by continuous lipid oxidative damage and sustained depletion of enzymatic and non-enzymatic antioxidant defenses, with a vascular component suggested by reduced nitric oxide levels, regardless of the time elapsed since symptom onset.
- Open Access
Evaluation of the Hematological Patterns from Up to 985 Days of Long COVID: A Cross-Sectional Study
Long COVID affects many individuals following acute coronavirus disease 2019 (COVID-19), and hematological changes can persist after the acute COVID-19 phase. This study aimed to evaluate these hematological laboratory markers, linking them to clinical findings and long-term outcomes in patients with long COVID. This cross-sectional study selected participants from a ‘long COVID’ clinical care program in the Amazon region. Clinical data and baseline demographics were obtained, and blood samples were collected to quantify erythrogram-, leukogram-, and plateletgram-related markers. Long COVID was reported for up to 985 days. Patients hospitalized in the acute phase had higher mean red/white blood cell, platelet, and plateletcrit levels and red blood cell distribution width. Furthermore, hematimetric parameters were higher in shorter periods of long COVID than in longer periods. Patients with more than six concomitant long COVID symptoms had a higher white blood cell count, a shorter prothrombin time (PT), and increased PT activity. Our results indicate there may be a compensatory mechanism for erythrogram-related markers within 985 days of long COVID. Increased levels of leukogram-related markers and coagulation activity were observed in the worst long COVID groups, indicating an exacerbated response after the acute disturbance, which is uncertain and requires further investigation.
Open AccessEvaluation of the Hematological Patterns from Up to 985 Days of Long COVID: A Cross-Sectional Study
Long COVID affects many individuals following acute coronavirus disease 2019 (COVID-19), and hematological changes can persist after the acute COVID-19 phase. This study aimed to evaluate these hematological laboratory markers, linking them to clinical findings and long-term outcomes in patients with long COVID. This cross-sectional study selected participants from a ‘long COVID’ clinical care program in the Amazon region. Clinical data and baseline demographics were obtained, and blood samples were collected to quantify erythrogram-, leukogram-, and plateletgram-related markers. Long COVID was reported for up to 985 days. Patients hospitalized in the acute phase had higher mean red/white blood cell, platelet, and plateletcrit levels and red blood cell distribution width. Furthermore, hematimetric parameters were higher in shorter periods of long COVID than in longer periods. Patients with more than six concomitant long COVID symptoms had a higher white blood cell count, a shorter prothrombin time (PT), and increased PT activity. Our results indicate there may be a compensatory mechanism for erythrogram-related markers within 985 days of long COVID. Increased levels of leukogram-related markers and coagulation activity were observed in the worst long COVID groups, indicating an exacerbated response after the acute disturbance, which is uncertain and requires further investigation.
- Open Access
- 28 March 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (7) , 5281
Liver Function in Patients with Long-Term Coronavirus Disease 2019 of up to 20 Months: A Cross-Sectional Study
The long-term laboratory aspects of the effects of coronavirus disease 2019 (COVID-19) on liver function are still not well understood. Therefore, this study aimed to evaluate the hepatic clinical laboratory profile of patients with up to 20 months of long-term COVID-19. A total of 243 patients of both sexes aged 18 years or older admitted during the acute phase of COVID-19 were included in this study. Liver function analysis was performed. Changes were identified in the mean levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), gamma-glutamyl transferase (GGT), and ferritin. A ferritin level of >300 U/L was observed in the group that presented more changes in liver function markers (ALT, AST, and GGT). Age ≥ 60 years, male sex, AST level > 25 U/L, and GGT level ≥ 50 or 32 U/L were associated with an ALT level > 29 U/L. A correlation was found between ALT and AST, LDH, GGT, and ferritin. Our findings suggest that ALT and AST levels may be elevated in patients with long-term COVID-19, especially in those hospitalised during the acute phase. In addition, an ALT level > 29 U/L was associated with changes in the levels of other markers of liver injury, such as LDH, GGT, and ferritin.
- 28 March 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (7) , 5281
Open AccessLiver Function in Patients with Long-Term Coronavirus Disease 2019 of up to 20 Months: A Cross-Sectional Study
The long-term laboratory aspects of the effects of coronavirus disease 2019 (COVID-19) on liver function are still not well understood. Therefore, this study aimed to evaluate the hepatic clinical laboratory profile of patients with up to 20 months of long-term COVID-19. A total of 243 patients of both sexes aged 18 years or older admitted during the acute phase of COVID-19 were included in this study. Liver function analysis was performed. Changes were identified in the mean levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), gamma-glutamyl transferase (GGT), and ferritin. A ferritin level of >300 U/L was observed in the group that presented more changes in liver function markers (ALT, AST, and GGT). Age ≥ 60 years, male sex, AST level > 25 U/L, and GGT level ≥ 50 or 32 U/L were associated with an ALT level > 29 U/L. A correlation was found between ALT and AST, LDH, GGT, and ferritin. Our findings suggest that ALT and AST levels may be elevated in patients with long-term COVID-19, especially in those hospitalised during the acute phase. In addition, an ALT level > 29 U/L was associated with changes in the levels of other markers of liver injury, such as LDH, GGT, and ferritin.
- Open Access
Metabolic Profile of Patients with Long COVID: A Cross-Sectional Study
A significant proportion of patients experience a wide range of symptoms following acute coronavirus disease 2019 (COVID-19). Laboratory analyses of long COVID have demonstrated imbalances in metabolic parameters, suggesting that it is one of the many outcomes induced by long COVID. Therefore, this study aimed to illustrate the clinical and laboratory markers related to the course of the disease in patients with long COVID. Participants were selected using a clinical care programme for long COVID in the Amazon region. Clinical and sociodemographic data and glycaemic, lipid, and inflammatory screening markers were collected, and cross-sectionally analysed between the long COVID-19 outcome groups. Of the 215 participants, most were female and not elderly, and 78 were hospitalised during the acute COVID-19 phase. The main long COVID symptoms reported were fatigue, dyspnoea, and muscle weakness. Our main findings show that abnormal metabolic profiles (such as high body mass index measurement and high triglyceride, glycated haemoglobin A1c, and ferritin levels) are more prevalent in worse long COVID presentations (such as previous hospitalisation and more long-term symptoms). This prevalence may suggest a propensity for patients with long COVID to present abnormalities in the markers involved in cardiometabolic health.
Open AccessMetabolic Profile of Patients with Long COVID: A Cross-Sectional Study
A significant proportion of patients experience a wide range of symptoms following acute coronavirus disease 2019 (COVID-19). Laboratory analyses of long COVID have demonstrated imbalances in metabolic parameters, suggesting that it is one of the many outcomes induced by long COVID. Therefore, this study aimed to illustrate the clinical and laboratory markers related to the course of the disease in patients with long COVID. Participants were selected using a clinical care programme for long COVID in the Amazon region. Clinical and sociodemographic data and glycaemic, lipid, and inflammatory screening markers were collected, and cross-sectionally analysed between the long COVID-19 outcome groups. Of the 215 participants, most were female and not elderly, and 78 were hospitalised during the acute COVID-19 phase. The main long COVID symptoms reported were fatigue, dyspnoea, and muscle weakness. Our main findings show that abnormal metabolic profiles (such as high body mass index measurement and high triglyceride, glycated haemoglobin A1c, and ferritin levels) are more prevalent in worse long COVID presentations (such as previous hospitalisation and more long-term symptoms). This prevalence may suggest a propensity for patients with long COVID to present abnormalities in the markers involved in cardiometabolic health.
- Open Access
- 27 February 2023
- Published by MDPI AG in Preprints.org
Evaluation of the Haematological Patterns from up to 985 Days of Long COVID: A Cross-Sectional Study
Long COVID affects a significant number of people after acute coronavirus disease 2019 (COVID-19), and haematological changes can persist in the COVID-19 phase. This study aimed to evaluate these haematological laboratory markers, linking them to clinical findings and long-term outcomes in patients with long COVID. This cross-sectional study selected participants from a ‘long COVID’ clinical care programme in the Amazon region. Clinical data and baseline demographics were obtained, and blood samples were collected for quantification of erythrogram-, leukogram-, and plateletgram-related markers. Long COVID was reported for up to 985 days. Patients hospitalised in the acute phase had higher mean red/white cell, platelet, and plateletcrit levels and red cell distribution width. In addition, haematimetric parameters were higher in shorter periods of long COVID. Patients presenting with more than six concomitant long COVID symptoms had a higher white blood cell count, shorter prothrombin time (PT), and increased PT activity. Within up to 985 days of long COVID, our results suggest a probable benign compensation for erythrogram-related markers. Increased levels of leukogram-related markers and increased coagulation activity were observed in the worse long COVID groups, also indicating an exacerbated response after the acute disturbance, which is uncertain and requires further investigation.
- 27 February 2023
- Published by MDPI AG in Preprints.org
Open AccessEvaluation of the Haematological Patterns from up to 985 Days of Long COVID: A Cross-Sectional Study
Long COVID affects a significant number of people after acute coronavirus disease 2019 (COVID-19), and haematological changes can persist in the COVID-19 phase. This study aimed to evaluate these haematological laboratory markers, linking them to clinical findings and long-term outcomes in patients with long COVID. This cross-sectional study selected participants from a ‘long COVID’ clinical care programme in the Amazon region. Clinical data and baseline demographics were obtained, and blood samples were collected for quantification of erythrogram-, leukogram-, and plateletgram-related markers. Long COVID was reported for up to 985 days. Patients hospitalised in the acute phase had higher mean red/white cell, platelet, and plateletcrit levels and red cell distribution width. In addition, haematimetric parameters were higher in shorter periods of long COVID. Patients presenting with more than six concomitant long COVID symptoms had a higher white blood cell count, shorter prothrombin time (PT), and increased PT activity. Within up to 985 days of long COVID, our results suggest a probable benign compensation for erythrogram-related markers. Increased levels of leukogram-related markers and increased coagulation activity were observed in the worse long COVID groups, also indicating an exacerbated response after the acute disturbance, which is uncertain and requires further investigation.
- Open Access
- 8 February 2023
- Published by MDPI AG in Preprints.org
Liver Function in Patients Up to 20 Months of Long COVID: A Cross-Sectional Study
The long-term laboratory aspects of the effects of COVID-19 on liver function are still not well understood. Therefore, this study aimed to evaluate the hepatic clinical-laboratory profile of patients with up to 20 months of long-term COVID-19. A total of 243 patients of both sexes aged 18 years or older hospitalised in the acute phase of COVID-19 were included in this study. Liver function analysis was performed. Changes were identified in the mean levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), gamma-glutamyl transferase (GGT), and ferritin. Inflammatory markers such as ferritin > 300 U/L were observed in the group that presented more changes in liver function markers (ALT, AST, and GGT). Age ≥ 60 years, male sex, AST > 25 U/L, and GGT ≥ 50 or 32 U/L were associated with ALT > 29 U/L. There was a correlation between ALT and AST, LDH, GGT, and ferritin. Our findings suggest that ALT and AST levels may be elevated in patients with long-term COVID, especially in those hospitalised in the acute phase. In addition, ALT > 29 U/L was associated with other markers of liver injury, such as LDH, GGT, and ferritin.
- 8 February 2023
- Published by MDPI AG in Preprints.org
Open AccessLiver Function in Patients Up to 20 Months of Long COVID: A Cross-Sectional Study
The long-term laboratory aspects of the effects of COVID-19 on liver function are still not well understood. Therefore, this study aimed to evaluate the hepatic clinical-laboratory profile of patients with up to 20 months of long-term COVID-19. A total of 243 patients of both sexes aged 18 years or older hospitalised in the acute phase of COVID-19 were included in this study. Liver function analysis was performed. Changes were identified in the mean levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), gamma-glutamyl transferase (GGT), and ferritin. Inflammatory markers such as ferritin > 300 U/L were observed in the group that presented more changes in liver function markers (ALT, AST, and GGT). Age ≥ 60 years, male sex, AST > 25 U/L, and GGT ≥ 50 or 32 U/L were associated with ALT > 29 U/L. There was a correlation between ALT and AST, LDH, GGT, and ferritin. Our findings suggest that ALT and AST levels may be elevated in patients with long-term COVID, especially in those hospitalised in the acute phase. In addition, ALT > 29 U/L was associated with other markers of liver injury, such as LDH, GGT, and ferritin.